WuXi AppTec: First Take: Stronger Than Expected Across Growth, Margins and FY26 Outlook

Research evidence excerpt

WuXi AppTec: First Take: Stronger Than Expected Across Growth, Margins and FY26 Outlook

Asia Pacific Equity Research

04 August 2026

This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of

Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.

WuXi AppTec

First Take: Stronger Than Expected Across Growth,

Margins and FY26 Outlook

Our First Take: WuXi AppTec delivered a very strong 2Q26 result, with Healthcare

sales and adj net profit materially ahead of our expectations (see our AC Yang Huang

preview on China CXO note), by 25% and 47% respectively, supportive of (852) 2800 3812

further earnings upgrades. Importantly, management raised FY26E yang.huang@jpmorgan.com

revenue guidance to RMB58.5-60.5bn from RMB51.3-53.0bn and now J.P. Morgan Securities (Asia Pacific) Limited/

J.P. Morgan Broking (Hong Kong) Limited

expects continuing operations revenue growth of 35-39% YoY versus 18-

Derek Choi

22% before. While some investors may still ask about the ongoing DoD (852) 2800-8744

1260H litigation and potential demand impact, the magnitude of the derek.c.choi@jpmorgan.com

guidance raise and backlog growth (+25.2% YoY) should reinforce J.P. Morgan Securities (Asia Pacific) Limited/

confidence that underlying demand for WuXi Apptec remains J.P. Morgan Broking (Hong Kong) Limited

exceptionally strong. Eric Zhao, CFA

(86-21) 6106 6256

Key Positives eric.zhao@jpmorgan.com

SAC Registration Number: S1730524050001

• 2Q26 revenue grew 48% YoY to RMB16.5bn, while adjusted non- J.P. Morgan Securities (China) Company

IFRS net profit surged 92% YoY to RMB7.0bn, implying a 42.4% Limited